These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8060755)

  • 41. Epithelial and stromal estrogen and progesterone receptor expression in endometrial cancer: true color computer-assisted image analysis versus subjective scoring.
    Kohlberger PD; Kieback DG; Breitenecker F; Loesch A; Gitsch G; Kainz C; Breitenecker G
    Gynecol Oncol; 1997 Mar; 64(3):404-10. PubMed ID: 9062141
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytologic diagnosis of low grade endometrial stromal sarcoma by staining for estrogen and progesterone receptors.
    Reich O; Pickel H; Regauer S
    Acta Cytol; 2002; 46(4):790-2. PubMed ID: 12146057
    [No Abstract]   [Full Text] [Related]  

  • 43. [Study on the treatment of high dose mifepristone and progesterone in endometrial carcinoma].
    Li CZ; Wen ZQ; Lan SM; Wang JY; Liu Y
    Zhonghua Fu Chan Ke Za Zhi; 2003 Sep; 38(9):552-5. PubMed ID: 14680611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of in vivo and in vitro responses of endometrial adenocarcinoma to progestins.
    Holinka CF; Deligdisch L; Deppe G; Fleming H; Namit C; de la Pena MM; Gurpide E
    Adv Exp Med Biol; 1981; 138():365-76. PubMed ID: 6211063
    [No Abstract]   [Full Text] [Related]  

  • 45. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.
    Falcón O; Chirino R; León L; López-Bonilla A; Torres S; Fernández L; García-Hernández JA; Valerón PF; Díaz-Chico JC
    Br J Cancer; 1999 Feb; 79(3-4):570-6. PubMed ID: 10027332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneity and progesterone-receptor distribution in endometrial adenocarcinoma.
    Mortel R; Zaino R; Satyaswaroop PG
    Cancer; 1984 Jan; 53(1):113-6. PubMed ID: 6689993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic impact of morphometric nuclear grade of endometrial carcinoma.
    Salvesen HB; Iversen OE; Akslen LA
    Cancer; 1998 Sep; 83(5):956-64. PubMed ID: 9731900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer.
    Seeger A; Kölbl H; Petry IB; Gebhard S; Battista MJ; Böhm D; Steiner E
    Gynecol Oncol; 2012 Apr; 125(1):200-7. PubMed ID: 22210468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The association between c-fos and c-jun expression and estrogen and progesterone receptors is lost in human endometrial cancer.
    Salmi A; Carpén O; Rutanen E
    Tumour Biol; 1999; 20(4):202-11. PubMed ID: 10393530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progesterone receptor content in endometrial carcinoma correlates with serum levels of free estradiol.
    Nyholm HC; Nielsen AL; Lyndrup J; Thorpe SM
    Acta Obstet Gynecol Scand; 1993 Oct; 72(7):565-9. PubMed ID: 8213106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The prognostic significance of progesterone receptor level in endometrial cancer].
    Nyholm HC; Christensen IJ; Nielsen AL
    Ugeskr Laeger; 1997 Jan; 159(5):601-4. PubMed ID: 9045451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status.
    Koshiyama M; Konishi I; Wang DP; Mandai M; Komatsu T; Yamamoto S; Nanbu K; Naito MF; Mori T
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):265-71. PubMed ID: 8236823
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma.
    Punnonen R; Mattila J; Kuoppala T; Koivula T
    J Cancer Res Clin Oncol; 1993; 119(7):426-9. PubMed ID: 8491764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progestin action and progesterone receptors in breast cancer.
    Chamness GC
    Cancer Res; 1989 Dec; 49(24 Pt 1):7176-9. PubMed ID: 2582458
    [No Abstract]   [Full Text] [Related]  

  • 55. Progesterone therapy in endometrial cancer.
    Tomao F; Panici PB; Tomao S
    Am J Obstet Gynecol; 2018 Mar; 218(3):362-363. PubMed ID: 29175256
    [No Abstract]   [Full Text] [Related]  

  • 56. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
    Lax SF
    Virchows Arch; 2004 Mar; 444(3):213-23. PubMed ID: 14747944
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oestrogen and progestin receptors as prognostic indicators in endometrial cancer. A review of the literature.
    Kauppila A
    Acta Oncol; 1989; 28(4):561-6. PubMed ID: 2675940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Basis of gestagen therapy of endometrial carcinoma].
    Trams G
    Dtsch Med Wochenschr; 1978 Mar; 103(13):574-7. PubMed ID: 639688
    [No Abstract]   [Full Text] [Related]  

  • 59. 5-year survival rate in endometrial carcinoma stage I-II related to steroid receptor concentration, degree of differentiation, age and myometrial invasion.
    Lindahl B; Fernö M; Gullberg B; Norgren A; Willén R
    Anticancer Res; 1992; 12(2):409-12. PubMed ID: 1580559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormonal treatment of endometrial cancer: past, present and future.
    Podczaski E; Mortel R
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):469-89. PubMed ID: 11476566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.